Back to Search
ELIZABETH BUCK MD
MD
Family Medicine Physician
NPI: 1265054514IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
ML61073964(WA)MD61341875(WA)
Education
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE
Class of 2020
Research & Publications (20)
Electron energy-loss spectroscopy of anomalous plutonium behavior in nuclear waste materials.
PMID 15003610·Micron·2004
8-other
Precipitation of nitrate-cancrinite in Hanford Tank Sludge.
PMID 15382874·Environ Sci Technol·2004
8-other
Ullmann diaryl ether synthesis: rate acceleration by 2,2,6,6-tetramethylheptane-3,5-dione.
PMID 11975644·Org Lett·2002
8-other
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.
PMID 18236164·Clin Exp Metastasis·2008
6-review
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
PMID 18922904·Cancer Res·2008
7-preclinical
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
PMID 17671083·Mol Cancer Ther·2007
7-preclinical
Phosphorylation of threonine residue 276 is required for acute regulation of serotonin transporter by cyclic GMP.
PMID 17310063·J Biol Chem·2007
7-preclinical
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.
PMID 17308052·Mol Cancer Ther·2007
8-other
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
PMID 16928826·Mol Cancer Ther·2006
8-other
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
PMID 17121914·Mol Cancer Ther·2006
7-preclinical
How to utilize benchmarking in the clinical laboratory.
PMID 17132459·Clin Leadersh Manag Rev·2006
8-other
Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor.
PMID 15710877·Proc Natl Acad Sci U S A·2005
8-other
Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor.
PMID 15550394·J Biol Chem·2005
7-preclinical
Neptunium(V) partitioning to uranium(VI) oxide and peroxide solids.
PMID 15984790·Environ Sci Technol·2005
8-other
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
PMID 16230409·Cancer Res·2005
7-preclinical
Practical synthesis of a potent hepatitis C virus RNA replication inhibitor.
PMID 15357584·J Org Chem·2004
8-other
Organization and functions of interacting domains for signaling by protein-protein interactions.
PMID 14625370·Sci STKE·2003
6-review
Methanethiosulfonate ethylammonium block of amine currents through the ryanodine receptor reveals single pore architecture.
PMID 12963712·J Biol Chem·2003
7-preclinical
Role of dynamic interactions in effective signal transfer for Gbeta stimulation of phospholipase C-beta 2.
PMID 12388553·J Biol Chem·2002
7-preclinical
Use of peptide probes to determine function of interaction sites in G protein interactions with effectors.
PMID 11771407·Methods Enzymol·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via COLUMBIA VALLEY COMMUNITY HEALTH · 4 locations total
- Address
- 105 S APPLE BLOSSOM DR
CHELAN, WA 98816 - Phone
- (509) 682-6000
Locations (4)
Quick Facts
- NPI
- 1265054514
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 4
- Years in Practice
- 6
- Publications
- 20
Are you this provider?
Claim Your Profile